Published: 4 January 2022
Author(s): Jesús Fernando García-Cruces-Méndez, Luis Corral-Gudino, María Piedad Del-Amo-Merino, José María Eiros-Bouza, Marta Domínguez-Gil González
Issue: March 2022
Section: Letter to the Editor

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared in late 2019. Since then, SARS-CoV-2 spread worldwide and led to a health crisis due to coronavirus disease (COVID-19). To fight against this pandemic, several vaccines against SARS-CoV-2 were developed [1]. Two mRNA vaccines, BNT162b2 from Pfizer-BioNTech and mRNA-1273 from Moderna, were the first to be approved and administered since December 2020. Pivotal studies reported high seroconversion rates after mRNA SARS-CoV-2 vaccination [2].

Newsletters

Stay informed on our latest news!